Pharmacokinetics and normal scintigraphic appearance of 99mtc aprotinin

Sally M. Sojan; Douglas R. Smyth; Chris Tsopelas; David Mudge; Peter J. Collins; Barry E. Chatterton

doi:10.1097/00006231-200506000-00009

Pharmacokinetics and normal scintigraphic appearance of ^99mtc aprotinin

Sally M. Sojan, Douglas R. Smyth, Chris Tsopelas, David Mudge, Peter J. Collins, Barry E. Chatterton

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Abstract

To confirm the pharmacokinetics and biodistribution of ^99mTc aprotinin in normal volunteers and to determine the optimum time for scanning post-injection, prior to further investigations of ^99mTc aprotinin as an imaging agent for amyloidosis.

Original language	English
Pages (from-to)	535-539
Number of pages	5
Journal	Nuclear Medicine Communications
Volume	26
Issue number	6
DOIs	https://doi.org/10.1097/00006231-200506000-00009
Publication status	Published or Issued - Jun 2005
Externally published	Yes

Keywords

Amyloidosis
Aprotinin
Technetium

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1097/00006231-200506000-00009

Cite this

@article{c792d5c447c8498899c947b08b29bcca,

title = "Pharmacokinetics and normal scintigraphic appearance of 99mtc aprotinin",

abstract = "To confirm the pharmacokinetics and biodistribution of 99mTc aprotinin in normal volunteers and to determine the optimum time for scanning post-injection, prior to further investigations of 99mTc aprotinin as an imaging agent for amyloidosis.",

keywords = "Amyloidosis, Aprotinin, Technetium",

author = "Sojan, \{Sally M.\} and Smyth, \{Douglas R.\} and Chris Tsopelas and David Mudge and Collins, \{Peter J.\} and Chatterton, \{Barry E.\}",

year = "2005",

month = jun,

doi = "10.1097/00006231-200506000-00009",

language = "English",

volume = "26",

pages = "535--539",

journal = "Nuclear Medicine Communications",

issn = "0143-3636",

publisher = "Wolters Kluwer Health",

number = "6",

}

TY - JOUR

T1 - Pharmacokinetics and normal scintigraphic appearance of 99mtc aprotinin

AU - Sojan, Sally M.

AU - Smyth, Douglas R.

AU - Tsopelas, Chris

AU - Mudge, David

AU - Collins, Peter J.

AU - Chatterton, Barry E.

PY - 2005/6

Y1 - 2005/6

N2 - To confirm the pharmacokinetics and biodistribution of 99mTc aprotinin in normal volunteers and to determine the optimum time for scanning post-injection, prior to further investigations of 99mTc aprotinin as an imaging agent for amyloidosis.

AB - To confirm the pharmacokinetics and biodistribution of 99mTc aprotinin in normal volunteers and to determine the optimum time for scanning post-injection, prior to further investigations of 99mTc aprotinin as an imaging agent for amyloidosis.

KW - Amyloidosis

KW - Aprotinin

KW - Technetium

UR - https://www.scopus.com/pages/publications/20144385088

U2 - 10.1097/00006231-200506000-00009

DO - 10.1097/00006231-200506000-00009

M3 - Article

C2 - 15891597

AN - SCOPUS:20144385088

SN - 0143-3636

VL - 26

SP - 535

EP - 539

JO - Nuclear Medicine Communications

JF - Nuclear Medicine Communications

IS - 6

ER -